ABSTRACT
Aims This short study was performed to better understand the time frame associated with changes in SARS-CoV-2 nucleic acid testing and provide recommendations for repeat testing. Recommendations were useful as little guidance is available for repeat testing in patients being followed expectantly for changes in disease.
Methods A review of laboratory data of tests for SARS-CoV-2 nucleic acid was performed selecting patients who had changing results. Time between changes in test results was determined to provide guidance for repeat testing.
Results The interquartile range of data for patients who had a negative to positive change in lab testing (“progression”) was 6-16 days (Median 9). The interquartile range of data for patients who had a positive to negative change in test results (“remission”) was 9-21 days (Median 14).
Conclusion Because sampling of the nares or nasopharynx can be variable, repeat testing should be performed swiftly when symptomatic patients are negative. The data in this short study varies widely, so authors recommend repeat testing during a period of time associated with the interquartile range or median (see results above).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
BRANY IRB, brany.com, File # 20-12-234-337(c20)/ Investigator Initiated Protocol 20-102
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data, blinded to study participant identifiers, is available to reviewers upon request.
